怀孕期间肝脏梗塞:系统性审查
Bryce T Munter1, Angela R Boyd1, Raphaela Tchani1
1University of Texas Health Science Center at San Antonio, San Antonio, TX (Drs Munter and Boyd, Ms Tchani and Dr Ramsey).
American journal of obstetrics & gynecology MFM
|April 15, 2024
概括
怀孕期间的肝脏梗塞很少发生,但与HELLP综合征有关. 通过CT扫描及时诊断和包括抗凝药和类固醇在内的管理对于孕产妇和胎儿的结果至关重要.
科学领域:
- 产科和妇科 产科和妇科
- 肝病学 肝病学是一种肝病学.
- 关键护理医学 关键护理医学
背景情况:
- 肝脏梗塞是一种罕见的妊娠并发症,通常与血液溶解,肝酶升高和低血小板 (HELLP) 综合征有关.
- 了解风险因素,诊断方法和管理策略对于改善结果至关重要.
结论:
- 在HELLP综合征病例中应怀疑肝脏梗塞,特别是在表现为腹痛的抗脂综合征患者中.
- 脑电图扫描是主要的诊断工具.
- 建议立即多式管理,包括抗凝药和类固醇.
相关概念视频
Teratogenicity
4.2K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
4.2K
Ischemic Heart Disease: Overview
3.9K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
3.9K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
386
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
386
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
275
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
275
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
387
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
387
Hepatic Encephalopathy
71
DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic...
71


